Ex Parte LEE - Page 19


                 Appeal No.  2004-1369                                                        Page 19                  
                 Application No.  08/966,233                                                                           
                 degree of specificity that GDF-1 will share the activity of a particular TGF-β                        
                 isoform, or any other particular member of the TGF-β superfamily to which GDF-                        
                 1 is least homologous with.                                                                           
                        Accordingly, we also disagree with appellant’s assertion (Brief, page 9)                       
                 that “the [e]xaminer provides no evidence that those of skill in the art at the time                  
                 the invention was made would have believed that members of the TGF-β super                            
                 family exhibit such diverse activities as to preclude prediction of function based                    
                 on this family assignment.”  In our opinion, as discussed above, the evidence                         
                 relied upon by appellant – Akhurst – speaks for itself.                                               
                        Thus, while appellant asserts (Brief, page 9), the specification “predicted                    
                 that the GDF-1 protein was likely to play an important role in mediating                              
                 developmental decisions related to cell differentiation…,” appellant’s                                
                 specification fails to identify what precise role GDF-1 plays.  In this regard, we                    
                 agree with the examiner (Answer, page 15), “the specification is an invitation to                     
                 experiment without clear direction or guidance as to the particular biological                        
                 activity to investigate.”                                                                             


                 III.  Post-filing date evidence:                                                                      
                        Appellant asserts (Brief, page 10), “[t]he Rankin reference was submitted                      
                 to demonstrate that the GDF-1 protein has the utilities that were predicted in the                    
                 specification, and is suitable evidence for that purpose even though it was                           
                 published after the filing date of the present application.”  In this regard,                         
                 appellant asserts (id.), Rankin’s “results with the GDF-1 knockout mouse prove                        







Page:  Previous  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  Next 

Last modified: November 3, 2007